Teva’s press relations staffers in the US must have thought they were simply doing their job, unaware that Teva’s upper management has been misrepresenting the status of the Lovenox ANDA to the investment community. I’ll bet Teva declines to answer any questions about Lovenox on its next quarterly CC.
Market Data 
Markets 
AI
